SEC INSIDER TRANSACTIONS

Medtronic plc (MDT) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

MDT · Medtronic plc

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-10-27 · 29 filings · fetched 2026-10-27T16:20:59Z

Recent reported activity

0purchase rows on this page

3sale rows on this page

59matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-08-03Filed 2026-08-04	KIIL HARRY SKIPOfficer · EVP & President Cardiovascular Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 286 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 23,074 shares will be issued. If maximum performance metrics are achieved, 55,378 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F7	A Award / grantStock Option (Right to Buy) · Derivative	65,556A	0	Direct	Form 4 ↗0001708062-26-000010
2026-08-03Filed 2026-08-04	KIIL HARRY SKIPOfficer · EVP & President Cardiovascular Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 286 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 23,074 shares will be issued. If maximum performance metrics are achieved, 55,378 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F4, F5, F6	A Award / grantPerformance Share Units · Derivative	23,074A	0	Direct	Form 4 ↗0001708062-26-000010
2026-08-03Filed 2026-08-04	KIIL HARRY SKIPOfficer · EVP & President Cardiovascular Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 286 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 23,074 shares will be issued. If maximum performance metrics are achieved, 55,378 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F3	A Award / grantOrdinary Shares · Non-derivative	9,230A	0	Direct	Form 4 ↗0001708062-26-000010
2026-08-03Filed 2026-08-04	Martha GeoffreyDirector · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 980 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 103,831 shares will be issued. If maximum performance metrics are achieved, 249,194 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F7	A Award / grantStock Option (Right to Buy) · Derivative	273,150A	0	Direct	Form 4 ↗0001560409-26-000008
2026-08-03Filed 2026-08-04	Martha GeoffreyDirector · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 980 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 103,831 shares will be issued. If maximum performance metrics are achieved, 249,194 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F7	A Award / grantStock Option (Right to Buy) · Derivative	295,002A	0	Direct	Form 4 ↗0001560409-26-000008
2026-08-03Filed 2026-08-04	Martha GeoffreyDirector · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 980 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 103,831 shares will be issued. If maximum performance metrics are achieved, 249,194 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F4, F5, F6	A Award / grantPerformance Share Units · Derivative	103,831A	0	Direct	Form 4 ↗0001560409-26-000008
2026-08-03Filed 2026-08-04	Martha GeoffreyDirector · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 980 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 103,831 shares will be issued. If maximum performance metrics are achieved, 249,194 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F3	A Award / grantOrdinary Shares · Non-derivative	41,533A	0	Direct	Form 4 ↗0001560409-26-000008
2026-07-31Filed 2026-08-04	Thompson KweliOfficer · EVP & President, Neuroscience Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 188 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 17,306 shares will be issued. If maximum performance metrics are achieved, 41,534 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F1, F2	F WithholdingOrdinary Shares · Non-derivative	1,739D	85.39	Direct	Form 4 ↗0002137804-26-000004
2026-07-31Filed 2026-08-04	Blomquist Denise L.Officer · Chief Accounting Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 136 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 2,337 shares will be issued. If maximum performance metrics are achieved, 5,609 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F1, F2	F WithholdingOrdinary Shares · Non-derivative	212D	85.39	Direct	Form 4 ↗0002061393-26-000012
2026-07-31Filed 2026-08-04	Walter Matthew R.Officer · SVP, Chief HR Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 140 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 14,421 shares will be issued. If maximum performance metrics are achieved, 34,610 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F1, F2	F WithholdingOrdinary Shares · Non-derivative	1,675D	85.39	Direct	Form 4 ↗0002028475-26-000010
2026-07-31Filed 2026-08-04	Marinaro MichaelOfficer · EVP, Pres MedSurg and Americas Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 547 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Represents restricted stock units that vest in four annual installments beginning one year from the date of grant. F5 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F6 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F7 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 27,400 shares will be issued. If maximum performance metrics are achieved, 65,760 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F8 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F1, F2	F WithholdingOrdinary Shares · Non-derivative	3,356D	85.39	Direct	Form 4 ↗0001984186-26-000006
2026-07-31Filed 2026-08-04	KIIL HARRY SKIPOfficer · EVP & President Cardiovascular Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 286 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 23,074 shares will be issued. If maximum performance metrics are achieved, 55,378 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F1, F2	F WithholdingOrdinary Shares · Non-derivative	3,074D	85.39	Direct	Form 4 ↗0001708062-26-000010
2026-07-31Filed 2026-08-04	Martha GeoffreyDirector · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 980 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3 Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6 The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 103,831 shares will be issued. If maximum performance metrics are achieved, 249,194 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. References: F1, F2	F WithholdingOrdinary Shares · Non-derivative	15,810D	85.39	Direct	Form 4 ↗0001560409-26-000008
2026-07-28Filed 2026-07-29	Quinn MichelleOfficer · EVP, GC and Secretary Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2 Includes 697 shares acquired through dividend reinvestment since the last report filed by the reporting person. References: F1, F2	F WithholdingOrdinary Shares · Non-derivative	2,069D	86.88	Direct	Form 4 ↗0001964281-26-000002
2026-07-08Filed 2026-07-09	Walter Matthew R.Officer · SVP, Chief HR Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Includes 107 shares acquired under Medtronic's Employee Stock Ownership Plan since the last report filed by the reporting person. References: F1	S Sale (market/private)Ordinary Shares · Non-derivative	3,102D	83.15	Direct	Form 4 ↗0002028475-26-000008
2026-06-08Filed 2026-06-09	KIIL HARRY SKIPOfficer · EVP & President Cardiovascular Filing context Reported filing row; may be amended. Do not sum filings blindly. References:	S Sale (market/private)Ordinary Shares · Non-derivative	228D	80.45	Direct	Form 4 ↗0001708062-26-000008
2026-06-08Filed 2026-06-09	KIIL HARRY SKIPOfficer · EVP & President Cardiovascular Filing context Reported filing row; may be amended. Do not sum filings blindly. References:	S Sale (market/private)Ordinary Shares · Non-derivative	3,961D	80.44	Direct	Form 4 ↗0001708062-26-000008
2026-06-05Filed 2026-06-08	Blomquist Denise L.Officer · Chief Accounting Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on April 24, 2026. References: F1	F WithholdingOrdinary Shares · Non-derivative	237D	83.32	Direct	Form 4 ↗0002061393-26-000010
2026-06-04Filed 2026-06-08	Walter Matthew R.Officer · SVP, Chief HR Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on April 24, 2026. References: F1	F WithholdingOrdinary Shares · Non-derivative	2,840D	83.32	Direct	Form 4 ↗0002028475-26-000006
2026-06-04Filed 2026-06-08	Marinaro MichaelOfficer · EVP, Pres MedSurg and Americas Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on April 24, 2026. References: F1	F WithholdingOrdinary Shares · Non-derivative	7,471D	83.32	Direct	Form 4 ↗0001984186-26-000004
2026-06-04Filed 2026-06-08	KIIL HARRY SKIPOfficer · EVP & President Cardiovascular Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on April 24, 2026. References: F1	F WithholdingOrdinary Shares · Non-derivative	6,817D	83.32	Direct	Form 4 ↗0001708062-26-000006
2026-06-04Filed 2026-06-08	Martha GeoffreyDirector · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on April 24, 2026. References: F1	F WithholdingOrdinary Shares · Non-derivative	41,936D	83.32	Direct	Form 4 ↗0001560409-26-000006
2026-05-26Filed 2026-05-28	Blomquist Denise L.Officer · Chief Accounting Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares issued upon the settlement of performance-vesting share units granted on July 31, 2023, based on performance as certified on May 26, 2026, of which 1,027 shares will be delivered to the reporting person when her employment with the Company ends. F2 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F3 The performance share units vested on April 24, 2026. References: F2, F3	M Exercise / conversionPerformance Share Unit · Derivative	1,621D	0	Direct	Form 4 ↗0002061393-26-000008
2026-05-26Filed 2026-05-28	Blomquist Denise L.Officer · Chief Accounting Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares issued upon the settlement of performance-vesting share units granted on July 31, 2023, based on performance as certified on May 26, 2026, of which 1,027 shares will be delivered to the reporting person when her employment with the Company ends. F2 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F3 The performance share units vested on April 24, 2026. References: F1	M Exercise / conversionOrdinary Shares · Non-derivative	1,712A	0	Direct	Form 4 ↗0002061393-26-000008
2026-05-26Filed 2026-05-28	Walter Matthew R.Officer · SVP, Chief HR Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares issued upon the settlement of performance-vesting share units granted on July 31, 2023, based on performance as certified on May 26, 2026. F2 Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F3 The performance share units vested on April 24, 2026. References: F2, F3	M Exercise / conversionPerformance Share Unit · Derivative	8,449D	0	Direct	Form 4 ↗0002028475-26-000004

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.